Press Releases

• Tarcocimab clinical and non-clinical data highlight strong 6-month efficacy profile in diabetic retinopathy patients and continued favorable safety profile.
• KSI-501 clinical and non-clinical data highlight multiple ascending dose safety, bioactivity and durability in treatment-naïve and treatment-experienced patients and next steps of Phase 3 development for KSI-501 and Phase 1b development for KSI-101.
• Novel small molecules and protein therapeutics highlight... (continue reading...)

All figures quoted in U.S. dollars unless otherwise noted:

• 2024 Q1 revenue of $723 million; 1,127 equivalent units ("EUs") delivered, up 42% from 2023 Q1, with 201 of EUs delivered being battery- and fuel cell-electric buses ("ZEBs").
• Ending total backlog2 position (both firm and options) reached a record high of 14,783 EUs (valued at $11.7 billion), with 365 EUs in bid award pending; ZEBs represent 39% of total backlog2.
• 2024 Q1 Net loss of $9 million; Net loss... (continue reading...)

• Q1'24 net sales of $469.8 million, net income of $35.2 million and earnings per diluted share of $1.95
• Q1'24 non-GAAP net income of $37.7 million and non-GAAP earnings per diluted share of $2.09
• Delivered adjusted EBITDA of $83.3 million in Q1'24, a 6% increase compared to $78.8 million in Q1'23
• Gross margins improved 400 basis points compared to the prior year, the 7th consecutive quarterly year-over-year increase
• Generated $27.2 million of operating cash flow in... (continue reading...)

Raises Total Company Adjusted EBITDA and Adjusted EPS Guidance

First Quarter 2024 Highlights

(All comparisons against the first quarter of 2023 unless otherwise noted.)

Strong performance driven by its competitive differentiator - Ingersoll Rand Execution Excellence (IRX):

• First quarter orders of $1,707 million, down 4%, or down 7% organic
  • On a two-year stack, up 5%, or up 1% organic
• Reported first quarter revenues of $1,670 million, up 3%, or down 1%... (continue reading...)

ORLANDO, Fla., May 2, 2024 /PRNewswire/ -- Xenia Hotels & Resorts, Inc. (NYSE: XHR) ("Xenia" or the "Company") today announced results for the quarter ended March 31, 2024.

First Quarter 2024 Highlights

• Net Income: Net income attributable to common stockholders was $8.5 million, or $0.08 per share
• Adjusted EBITDAre: $65.3 million, decreased 8.5% compared to the first quarter of 2023
• Adjusted FFO per Diluted Share: $0.44, increased $0.04 compared to the first quarter of... (continue reading...)